# MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

> **NCT00797667** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 660 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Telcagepant 140 mg
- **DRUG:** Telcagepant 280 mg
- **DRUG:** 140 mg telcagepant placebo
- **DRUG:** 280 mg telcagepant placebo

## Key facts

- **NCT ID:** NCT00797667
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11-12
- **Primary completion:** 2009-05-20
- **Final completion:** 2009-05-20
- **Target enrollment:** 660 (ACTUAL)
- **Why stopped:** The study was terminated based on a recommendation of the DSMB following the identification of two patients with significant elevations in serum transaminases
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00797667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00797667, "MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00797667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*